Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

Hepatology

Volumn 26, Issue 2, 1997, Pages 473-477

  Bodenheimer Jr , Henry C ^a,f   Lindsay, Karen L ^b   Davis, Gary L ^c   Lewis, James H ^d   Thung, Swan N ^a   Seeff, Leonard B ^d,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 20644441571     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260231     Document Type: Article

References (22)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander J, Hu PY, et al. The natural history of community-acquired hepatitis C in the United Slates. N Engl J Med 1992;327:1899-1905.
2. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inque O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989;321:1501-1506.
4. DiBisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon-alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
6. Saracco G, Rosina F, Torrani-Cerenzia MR, Lattore V, Chiandussi L, Gallo V, Petrino R, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11:S43-S49.
7. DiBisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, et al. A pilot study of ribavirin therapy for chronic hepatitis C. HEPATOLOGY 1992;16:649-654.
8. Reichard O, Anderson J, Schvarcz. Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
9. Reichard O, Anderson J. Ribavirin: a possible alternative for the treatment of chronic non-A, non-B hepatitis. Scand J Infect Dis 1990;22:509.
10. Shindo M, DiBisceglie AM, Cheung L, Shih W-K, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-704.
11. Stayver L, Rossaur R, Wyseur AN, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characteristics of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
12. Knodell RG, Ishak KG , Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
13. Rodriguez WJ, Parrott RH. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect Dis Clin North Am 1987;1:425-439.
14. Patterson J, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-1146.
15. Allen L, Huffman JH, Sidwell RW. Failure of 1-b-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide (virazole, ICN 1229) to stimulate interferon. Antimicrob Ag Chemother 1973;3:534-535.
16. Reichard O, Yun Z-B, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;22:1-4.
17. DiBisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
18. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993;105:507-512.
19. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-412.
20. Ning Q, Brown D, Parodo J, Cattral M, Fung L, Liu M, Rotstein O, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves TH11 cytokine production, but inhibits TH2 cytokine response. HEPATOLOGY 1996;24:355A.
21. Regenstein F, Towbin B. Viral hepatitis: the emerging role of antiviral drugs. Drug Therapy 1993;93:29192-29200.
22. Brillanti S, Masci C, Miglioli M, Barbara L. Combination therapy with ribavirin and α-interferon in patients with chronic hepatitis C resistant to α-interferon treatment. Gastroenterology 1994;107:812-817.